Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mifepristone

Executive Summary

Second "approvable" letter for abortifacient (RU-486) sent to the Population Council Feb. 18. The drug was first deemed "approvable" on Sept. 18, 1996, pending resolution of manufacturing issues. The Population Council's licensee for mifepristone, Danco Laboratories, said it "is currently preparing information to satisfy the FDA's request." A timely response by Danco would allow FDA to clear the drug ahead of the Presidential nominating conventions this summer

You may also be interested in...



FDA Allocates $13.5 Mil. For Inspection Requirements In FY 2001 Budget

FDA wants to allocate $13.5 mil. in the FY 2001 budget request to come closer to its statutory obligations to conduct inspections. The requirements call for biennial inspections of most FDA-regulated facilities.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

UsernamePublicRestriction

Register

SC142962

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel